Sclerostin serum levels in patients with systemic autoimmune diseases
- 3 February 2016
- journal article
- Published by Portico in BoneKEy Reports
- Vol. 5, 775
- https://doi.org/10.1038/bonekey.2016.2
Abstract
Systemic autoimmune diseases (SADs) are associated with lower bone mass and an increased risk of fractures. Sclerostin has a pivotal role in bone metabolism. Available data on circulating sclerostin levels in healthy subjects are limited, whereas those in SAD patients are absent. Our objective was to determine circulating sclerostin concentrations in systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and Crohn's disease (CD) patients, and to analyze the factors associated with sclerostin concentrations. In this cross-sectional case-control study, serum sclerostin levels were measured in 38 SLE patients, 20 CD patients, 8 SSc patients and 20 healthy controls using a sclerostin ELISA. The mean values of the sclerostin (95% confidence interval) were 35.36 pmol l(-1) (12-101) in patients and 33.92 pmol l(-1) (2.31-100) in control subjects. The mean sclerostin value was 36.4 pmol l(-1) (22.1-48.5) in SLE patients, 26.7 pmol l(-1) (17.3-36.3) in CD patients and 51.8 pmol l(-1) (26.5-77.1) in SSc patients (P=0.001). Serum sclerostin levels were positively correlated with age (P<0.001), body mass index (BMI) (P=0.01) and lumbar spine Z-score (P=0.001) and negatively with creatinine clearance (P=0.001). Glucocorticoid treatment did not affect sclerostin levels. Sclerostin levels seem to have a heterogeneous pattern in different autoimmune diseases. SLE and SSc patients did not differ from healthy controls regarding sclerostin levels. The CD group had significantly lower values compared with SSc patients. Factors associated with sclerostin levels in autoimmune diseases seem to be the same than in the general population.Keywords
This publication has 28 references indexed in Scilit:
- The Relationships Between Serum Sclerostin, Bone Mineral Density, and Vascular Calcification in Rheumatoid ArthritisJournal of Clinical Endocrinology & Metabolism, 2014
- Association of Circulating Sclerostin With Bone Mineral Mass, Microstructure, and Turnover Biochemical Markers in Healthy Elderly Men and WomenJournal of Clinical Endocrinology & Metabolism, 2013
- Clinical utility of serum sclerostin measurementsBoneKEy Reports, 2013
- Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnoverJournal of Bone and Mineral Research, 2011
- Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatideOsteoporosis International, 2011
- Sclerostin: Current Knowledge and Future PerspectivesCalcified Tissue International, 2010
- Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitisArthritis & Rheumatism, 2009
- Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiationAGE, 2008
- RANKL–RANK signaling in osteoclastogenesis and bone diseaseTrends in Molecular Medicine, 2006
- Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing ProteinAmerican Journal of Human Genetics, 2001